We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+35.61%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$582M
AUM Growth
–
Cap. Flow
+$600M
Cap. Flow %
103.21%
Top 10 Hldgs %
91.48%
Holding
54
New
54
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$139M
2
NCNA
NuCana
NCNA
+$88.6M
3
OBSV
ObsEva SA Ordinary Shares
OBSV
+$58.3M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$46.7M
5
PDSB icon
PDS Biotechnology
PDSB
+$38.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
26
DELISTED
Radius Health, Inc.
RDUS
$605K 0.1%
+16,847
New +$609K
RETA
27
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$603K 0.1%
+29,383
New +$756K
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.23B
$523K 0.09%
+30,958
New +$469K
ARDX icon
29
Ardelyx
ARDX
$1.24B
$501K 0.09%
+99,166
New +$619K
REGN icon
30
Regeneron Pharmaceuticals
REGN
$68.8B
$449K 0.08%
+1,304
New +$454K
OTIC
31
DELISTED
Otonomy, Inc.
OTIC
$414K 0.07%
+98,624
New +$537K
GWPH
32
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$410K 0.07%
+3,637
New +$457K
ADMS
33
DELISTED
Adamas Pharmaceuticals
ADMS
$387K 0.07%
+16,206
New +$511K
DERM
34
DELISTED
Dermira, Inc.
DERM
$386K 0.07%
+48,320
New +$1.05M
CLSD
35
DELISTED
Clearside Biomedical
CLSD
$380K 0.07%
+2,359
New +$287K
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.35B
$374K 0.06%
+8,476
New +$431K
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$369K 0.06%
+72,017
New +$433K
RIGL icon
38
Rigel Pharmaceuticals
RIGL
$680M
$365K 0.06%
+10,297
New +$412K
CPRX
39
DELISTED
Catalyst Pharmaceutical
CPRX
$354K 0.06%
+148,055
New +$492K
MNOV icon
40
MediciNova
MNOV
$65M
$336K 0.06%
+32,875
New +$328K
KALA icon
41
KALA BIO
KALA
$11.8M
$323K 0.06%
+8
New +$304K
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$267K 0.05%
+8,688
New +$241K
RIGL icon
43
PUT
Rigel Pharmaceuticals
RIGL
$680M
$252K 0.04%
+7,130
New +$285K
SPPI
44
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$241K 0.04%
+15,000
New +$297K
OMED
45
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$213K 0.04%
+67,033
New +$185K
EXEL icon
46
CALL
Exelixis
EXEL
$13.9B
$206K 0.04%
+9,300
New +$257K
AFMD
47
DELISTED
Affimed
AFMD
$205K 0.04%
+11,083
New +$209K
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$203K 0.03%
+2,453
New +$278K
STML
49
DELISTED
Stemline Therapeutics, Inc.
STML
$193K 0.03%
+12,640
New +$197K
SNDX icon
50
Syndax Pharmaceuticals
SNDX
$1.84B
$173K 0.03%
+12,124
New +$129K
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2018 Portfolio in Review

Q1 2018 is the first quarter with a 13F filing on record for Sofinnova Investments, which disclosed 54 positions worth $582M. Its ten largest holdings account for 91% of the portfolio.

Its largest position is Ascendis Pharma A/S: 2,479,514 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets.

  • Sofinnova Investments's largest Q1 2018 buy was Ascendis Pharma A/S: 2,479,514 shares worth $162M.
  • Sofinnova Investments's ten largest holdings make up 91% of its $582M portfolio in Q1 2018.
  • Sofinnova Investments disclosed 54 positions in Q1 2018, its first 13F filing on record.

Based on Sofinnova Investments's 13F filing for Q1 2018, filed 15 May 2018.